EP Patent

EP4277916A1 — Synthetic ursolic acid derivatives and methods of use thereof

Assigned to Reata Pharmaceuticals Inc · Expires 2023-11-22 · 2y expired

What this patent protects

Disclosed herein are compounds of Formula (I-A), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, t…

USPTO Abstract

Disclosed herein are compounds of Formula (I-A), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, the present disclosure provides methods wherein the compounds and composition described herein are used for the treatment of diseases and disorders associated with inflammation and cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP4277916A1
Jurisdiction
EP
Classification
—
Expires
2023-11-22
Drug substance claim
No
Drug product claim
No
Assignee
Reata Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.